Genmab Feed

Land	Danmark
Lista	Large Cap Copenhagen
Sektor	Hälsovård
Industri	Bioteknik

2020-11-24 16:40:43 Genmab Announces Enapotamab Vedotin Update -2,90% | 444 MDKK

2020-11-10 20:57:54 Capital Increase in Genmab as a Result of Employee Warrant Exercise -0,39% | 457 MDKK

2020-11-10 13:59:37 Genmab to Present at Jefferies Virtual London Healthcare Conference -3,61% | 666 MDKK

2020-11-05 14:39:07 Genmab Announces Phase 3 Study Evaluating Epcoritamab in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma +6,18% | 1054 MDKK

2020-11-05 12:26:56 Genmab Announces that Janssen has Submitted a Type II Variation Application to the European Medicines Agency for use of Subcutaneous DARZALEX® (daratumumab) in Patients with Light-chain (AL) amyloidosis +6,18% | 1054 MDKK

2020-11-04 17:04:37 Genmab Announces Financial Results for the First Nine Months of 2020 +6,18% | 1054 MDKK

2020-11-04 16:13:40 Genmab Announces Data to be Presented at 2020 ASH Annual Meeting +7,96% | 552 MDKK

2020-10-30 12:15:37 Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami) -2,74% | 365 MDKK

2020-10-21 22:48:59 Genmab Announces IFM, HOVON and Janssen Achieve Positive Topline Results in Second Part of Phase 3 CASSIOPEIA Study of Daratumumab in Multiple Myeloma at Pre-planned Interim Analysis -0,90% | 352 MDKK

2020-10-15 15:02:54 Genmab to Host Capital Markets Day -3,80% | 434 MDKK

2020-10-14 23:15:38 Genmab Announces Data to be Presented at SITC 35th Anniversary Annual Meeting -3,80% | 434 MDKK

2020-10-13 12:42:26 Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2020 +0,54% | 486 MDKK

2020-10-07 23:13:39 Grant of Restricted Stock Units and Warrants to Employees in Genmab +1,38% | 300 MDKK

2020-09-30 18:56:10 Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons +1,30% | 580 MDKK

2020-09-29 21:48:44 Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons -2,29% | 645 MDKK

2020-09-29 21:36:54 Capital Increase in Genmab as a Result of Employee Warrant Exercise -2,29% | 645 MDKK

2020-09-22 23:04:38 Genmab Commences Binding Arbitration of Two Matters Under License Agreement with Janssen -5,18% | 2023 MDKK

2020-09-21 16:20:00 Genmab and Seattle Genetics Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020 -0,16% | 347 MDKK

2020-09-10 14:06:57 Genmab Announces that Janssen has Submitted a Supplemental Biologics License Application to U.S. FDA for use of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) in Patients with Light-chain (AL) Amyloidosis -0,88% | 221 MDKK

2020-09-09 14:47:52 Genmab to Present at Morgan Stanley 18th Annual Global Healthcare Conference +2,90% | 356 MDKK

2020-08-27 00:05:00 Genmab Announces Late-Breaking Oral Presentation of Phase 2 innovaTV 204 Study at the ESMO Virtual Congress 2020 +2,99% | 363 MDKK

2020-08-20 22:40:40 Genmab Announces Janssen Granted U.S. FDA Approval for DARZALEX® (daratumumab) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma +2,26% | 679 MDKK

2020-08-20 22:06:59 Genmab Announces Plan to Transition Arzerra® (ofatumumab) to an Oncology Access Program for Chronic Lymphocytic Leukemia Patients in the U.S. +2,26% | 679 MDKK

2020-08-20 19:33:38 U.S. FDA Approves Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis +2,26% | 679 MDKK

2020-08-18 21:40:10 Capital Increase in Genmab as a Result of Employee Warrant Exercise +0,13% | 372 MDKK

2020-08-12 17:23:54 Genmab Announces Financial Results for the First Half of 2020 +5,42% | 660 MDKK

2020-07-31 21:38:12 Genmab Announces European Myeloma Network and Janssen Achieve Positive Topline Results from Phase 3 APOLLO Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma +4,31% | 309 MDKK

2020-07-20 17:57:32 Major Shareholder Announcement +0,13% | 328 MDKK

2020-07-16 12:43:44 Genmab Announces Net Sales of DARZALEX® for the Second Quarter of 2020 -2,14% | 579 MDKK

2020-07-07 13:01:43 Major Shareholder Announcement +0,44% | 300 MDKK

2020-07-03 21:18:20 Major Shareholder Announcement +1,94% | 413 MDKK

2020-07-03 09:51:46 Major Shareholder Announcement -0,22% | 317 MDKK

2020-06-30 19:52:20 Capital Increase in Genmab as a Result of Employee Warrant Exercise -1,71% | 610 MDKK

2020-06-29 22:29:38 Genmab Announces Very Favorable Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer +2,35% | 660 MDKK

2020-06-10 12:00:40 Genmab and AbbVie Announce Broad Oncology Collaboration +4,29% | 1156 MDKK

2020-06-04 15:42:37 Genmab Announces European Marketing Authorization for the Subcutaneous Formulation of DARZALEX® (daratumumab) for the Treatment of Patients with Multiple Myeloma -1,77% | 899 MDKK

2020-06-04 14:09:52 Genmab to Participate in a Virtual Fireside Chat at the Goldman Sachs 41st Annual Global Healthcare Conference -1,77% | 899 MDKK

2020-06-03 21:57:51 Grant of Restricted Stock Units and Warrants to Employees in Genmab -1,77% | 899 MDKK

2020-06-02 22:36:20 U.S. FDA Extends Review of sBLA, Submitted by Novartis, for Ofatumumab in Relapsing Multiple Sclerosis -1,84% | 670 MDKK

2020-05-28 18:14:55 Genmab Announces Positive Topline Results in Phase III ANDROMEDA Study of Daratumumab in Light-chain (AL) Amyloidosis -0,63% | 1055 MDKK

2020-05-14 15:40:54 Genmab Announces Data to be Presented at the EHA25 Virtual Congress -1,37% | 581 MDKK

2020-05-12 19:11:03 Capital Increase in Genmab as a Result of Employee Warrant Exercise -0,23% | 944 MDKK

2020-05-06 17:01:26 Genmab Announces Financial Results for the First Quarter of 2020 +5,91% | 665 MDKK

2020-05-01 19:36:37 Genmab Announces U.S. FDA Approval of Subcutaneous Formulation of Daratumumab, DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj), for the Treatment of Patients with Multiple Myeloma -1,53% | 376 MDKK

2020-04-30 20:55:24 CHMP Issues Positive Opinion Recommending Subcutaneous Formulation of Daratumumab for the Treatment of Patients with Multiple Myeloma +2,08% | 188 MDKK

2020-04-29 21:04:17 Genmab Announces Data to be Presented at ASCO20 Virtual Scientific Program -0,49% | 249 MDKK

2020-04-14 12:35:50 Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2020 +2,25% | 575 MDKK

2020-04-01 22:19:48 Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons +0,18% | 314 MDKK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

2020-11-04	Kvartalsrapport 2020-Q3
2020-08-12	Kvartalsrapport 2020-Q2
2020-05-06	Kvartalsrapport 2020-Q1
2020-03-27	Ordinarie utdelning GMAB 0.00 DKK
2020-03-26	Årsstämma 2020
2020-02-19	Bokslutskommuniké 2019
2019-04-01	Ordinarie utdelning GMAB 0.00 DKK
2019-03-29	Årsstämma 2019
2018-11-14	Kvartalsrapport 2018-Q3
2018-08-08	Kvartalsrapport 2018-Q2
2018-05-08	Kvartalsrapport 2018-Q1
2018-04-11	Ordinarie utdelning GMAB 0.00 DKK
2018-04-10	Årsstämma 2018
2018-02-21	Bokslutskommuniké 2017
2017-11-08	Kvartalsrapport 2017-Q3
2017-08-09	Kvartalsrapport 2017-Q2
2017-05-10	Kvartalsrapport 2017-Q1
2017-03-29	Ordinarie utdelning GMAB 0.00 DKK
2017-03-28	Årsstämma 2017
2017-02-22	Bokslutskommuniké 2016
2016-11-10	Kapitalmarknadsdag 2016
2016-11-02	Kvartalsrapport 2016-Q3
2016-08-09	Kvartalsrapport 2016-Q2
2016-05-10	Kvartalsrapport 2016-Q1
2016-03-18	Ordinarie utdelning GMAB 0.00 DKK
2016-03-17	Årsstämma 2016
2016-02-17	Bokslutskommuniké 2015
2015-11-03	Kvartalsrapport 2015-Q3
2015-08-11	Kvartalsrapport 2015-Q2
2015-05-12	Kvartalsrapport 2015-Q1
2015-03-27	Ordinarie utdelning GMAB 0.00 DKK
2015-03-26	Årsstämma 2015
2015-03-02	Bokslutskommuniké 2014
2014-04-10	Ordinarie utdelning GMAB 0.00 DKK
2013-04-18	Ordinarie utdelning GMAB 0.00 DKK
2012-04-26	Ordinarie utdelning GMAB 0.00 DKK
2011-04-07	Ordinarie utdelning
2010-04-22	Ordinarie utdelning

Genmab

Beskrivning

Kalender

Genmab

Beskrivning

Kalender

Språk

Typ

År

Språk

Typ

Ett Mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden